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DiabetesAbstract Background: Statins with its anti-inﬂammatory and pleiotropic effects may prevent con-
trast induced nephropathy in high risk diabetic patients.
Aim of work: To compare between the effects of high and low dose atorvastatin on preventing con-
trast induced nephropathy after early coronary intervention in diabetic patients with acute coronary
syndrome.
Patients and methods: The study included 80 consecutive diabetic patients presented with acute
coronary syndrome and with normal renal function or with mild renal impairment (creatinine clear-
ance 60–90 ml/min) who underwent early percutaneous coronary intervention. Patients were ran-
domly assigned to one of two groups, Group (A) 40 patients who received 80 mg atorvastatin
12 h and 40 mg just before PCI. Group (B) 40 patients who received 10 mg atorvastatin at the same
time points. Samples were taken for serum creatinine and creatinine clearance before, at 12 h and at
72 h after PCI. Multivariable regression analysis did not identify any independent predictor of CIN.
Results: There were 5 cases of CIN in group A (12.5%) versus 7 in group B (17.5%), (p> 0.05).
The incidence of post-PCI contrast-induced nephropathy was not signiﬁcantly different between the
study groups (p> 0.05). Univariate regression analysis identiﬁed baseline blood urea (p= 0.012),
blood urea after 12 h (p= 0.030), and blood urea after 72 h (p= 0.003) as predictors of CIN.
330 H. Galal et al.Conclusion: No signiﬁcant difference between high and low doses of atorvastatin in preventing
CIN in diabetic patients with normal or mild renal impairment presenting with acute coronary syn-
drome who underwent early PCI.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
Contrast-induced nephropathy (CIN) is an important poten-
tial complication of percutaneous coronary intervention
(PCI). It occurs in approximately 7% of patients undergoing
cardiac procedures currently.1
Although the incidence of CIN has decreased due to
improved contrast media and better risk prevention measures
in the past decade, there are continued substantial increases
in CIN cases because of the increasing numbers of patients
undergoing PCI.2
CIN generally resolves spontaneously in most instances,
but patients may have prolonged hospital stay, increased risk
of in-hospital death and higher long-term mortality rates.3
There has been considerable interest in searching for effective
strategies to prevent CIN.
Beside peri-procedural hydration, pharmacological prophy-
lactic strategies have received considerable attention in recent
years.4 However, the pathophysiology of CIN is not well
known. Some studies have suggested that oxidative stress,
inﬂammation, reduction in renal blood ﬂow and direct tubular
cell damage by contrast media might play important roles in
the organ injury process.5
Statins inhibit (hepatic 3-hydroxy-3-methylglutaryl coen-
zyme A reductase) with consequent suppression of cholesterol
biosynthesis. The advent of these drugs has greatly impacted
the treatment of cardiovascular disease.6 In addition, several
clinical and basic science investigations have demonstrated
these statins may provide beneﬁcial effects outside of reductions
in low-density lipoproteins (LDL) and triglycerides (TG).7
Statins exert a number of protective effects involving the
improvement of endothelial function, stabilization of athero-
sclerotic plaque, decrease of oxidative stress and inﬂammation,
and inhibition of thrombogenic response8: the so-called pleio-
tropic effects. Their beneﬁt has also been largely demonstrated
in the setting of PCI by the prevention of peri-procedural myo-
cardial and renal damage.
2. Aim of the work
To compare between the effect of high-dose and low dose ator-
vastatin on preventing contrast induced nephropathy after
early percutaneous coronary intervention in diabetic patients
with acute coronary syndrome.
2.1. Methods
2.1.1. Study population
The study included 80 consecutive diabetic patients with NID-
DM with normal kidney function or mild renal impairment
(pre-procedural serum creatinine level P1.5 mg/dl or creati-
nine clearance between 60 and 90 ml/min) with acute coronarysyndrome (NSTE-ACS) who underwent PCI within 48 h of
symptom onset.
2.1.2. Patients were randomly assigned to one of two groups
Group (A) [40 patients] received 80 mg atorvastatin 12 h and
40 mg just before PCI. Group (B) [40 patients] received
10 mg atorvastatin at the same time points.
The design was single-blinded randomized controlled trial.
Investigators were aware of allocation group, while patients
were blinded. The method of randomization was consecutive
repetition, for example (patient 1 in group A, 2 in group B,
3 in group A, etc.).
The following patients were excluded from the study: ST ele-
vation myocardial infarction (STEMI), contra indication to
statins, liver impairment, exceeding maximum allowance of
contrast dose calculated as (4 · creatinine clearance) or (body
weight (kilograms) · 5 ml/serum creatinine), moderate to
severe renal impairment (serum creatinineP3 mg/dl or creati-
nine clearance 660 ml/min), and previous use of other statins.
2.1.3. Procedures
All patients were admitted in coronary care unit for monitor-
ing and investigations and received medications (Acetyl sali-
cylic acid, clopidogrel, anticoagulation, beta blockers and
angiotensin converting enzyme inhibitors, etc. according to
each case separately. All patients received atorvastatin
10 mg/day from the day of admission.
All patients were subjected to thorough history taking
together with full clinical examination including general and
local cardiac examination was done.
The following investigations were done for all patients: (1)
12 lead ECG. (2) Biomarkers: serial cardiac biomarkers (crea-
tine phosphokinase (CK), CKMB and troponin) on admission
and every 12 h. (3) Complete blood count, HbA1c (for diabetic
control), lipid proﬁle (Serum Cholesterol, Triglycerides level,
HDL Cholesterol level and LDL Cholesterol level), liver func-
tion tests (SGOT–SGPT). (4) Serum creatinine and creatinine
clearance (CrCl): by study design blood samples were drawn
before and at 12 and 72 h after PCI for measurement of serum
creatinine and the post-procedure peak value was used.
Creatinine clearance (CrCl) was calculated by the Cockcroft–
Gault formula: CrCl = ([140  age] · weight/serum creati-
nine · 72) with adjustment for female gender (CrCl female =
CrCl · 0.85).9 Patients with pre-existing renal impairment
received intravenous hydration with normal saline at 1 ml/h/
kg body weight for P12 h before and P24 h after
intervention.
Coronary angiography was done within 48 h of symptoms.
Clopidogrel preparation before PCI: patients who were not
receiving regular clopidogrel (75 mg daily) before the
procedure they were given 300–600 mg clopidogrel 4–8 h
before PCI.10
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signiﬁcant lesions using bare metal stents with balloon dilata-
tion for selective cases:
All interventions were performed with a nonionic, low-
osmolar (915 mOsm/kg), iodinated contrast agent.11 Proce-
dural success was deﬁned as post-procedure Thrombolysis In
Myocardial Infarction grade 3 ﬂow with decrease of stenosis
to <30% residual narrowing by quantitative coronary angio-
graphic analysis. All patients were monitored in the CCU for
at least 24 h for vital signs and detection of any vascular
complications.
2.2. Statistical analysis
 Qualitative data were presented as frequencies and
percentages. Chi-square (x2) test was used for studying
the comparisons between different qualitative variables.
Odds ratios (OR) and their 95% conﬁdence intervals (CI)
were used to study the association between different vari-
ables and the development of any vascular complications.
The (OR) is an estimate of relative risk. If the conﬁdence
interval for the odds ratio includes (1), this indicates none
statistically signiﬁcant association between the studied
variables. Continuous variables are expressed as num-
ber ± SD whereas categorical variables are expressed as
number (percentage %).
Quantitative data were presented as minimum, maximum,
means and standard deviation (SD) values. Student’s t-test
was used for comparisons between means of the two groups
(A and B).
Logistic regression model was constructed using CIN devel-
opment (Yes or No) as the dependent variable while clinical
data and demographic data were the independent (predictor)
variables. Forward stepwise regression method was used. In
this method, the independent variables with the highest
signiﬁcant scores are entered in the analysis. Finally, the model
tells us which independent (predictor) variables had the most
signiﬁcant effect on CIN development.
2.3. Results
The study included 80 consecutive diabetic patients with nor-
mal kidney function or mild renal impairment (NSTE-ACS)
who underwent PCI within 48 h of symptom onset.Table 1 Baseline clinical characteristics of the whole cohort and th
Whole cohort N= 80
Male gender 64(80%)
Age (years) 56.36 ± 9.20
Weight (kg) 85.88 ± 12.26
Hypertension 49(61.3%)
Smoking 41(51.3%)
Past history of IHD 37(46.3%)
Duration of DM (years) (mean ± SD)
UA 49(61.3%)
NSTEMI 31(38.7%)
Amount of contrast (ml) 241.25 ± 36.75
UA= unstable angina, NSTEMI= non ST-elevation myocardial infarc
* Signiﬁcant p-value.Table 1 showed the baseline clinical characteristics of the
whole cohort and the two study groups. All patients had type
II diabetes and all patients were on oral hypoglycemic treat-
ment. Weight was signiﬁcantly greater in group B than group
A (88.6 ± 12.4 versus 83.1 ± 11.6 kg respectively, p= 0.044).
Otherwise, the two groups were similar regarding the baseline
clinical characteristics (p> 0.05 for all).
Table 2 showed laboratory data of the whole cohort and
the two study groups. The mean serum creatinine on admis-
sion in whole cohort was 1.2 ± 0.2 mg/dl, after 12 h was
1.1 ± 0.2 mg/dl, and after 72 h was 1.2 ± 0.3 mg/dl. The
mean urea on admission, after 12 h, and after 72 h were
34.0 ± 9.9, 35.0 ± 8.9, 34.5 ± 9.7 mg/dl respectively. The
mean SGOT in whole cohort was 29.8 ± 6.5 mg/dl, while
the mean SGPT was 35.7 ± 9.7 mg/dl. Regarding lipid
proﬁle, the mean LDL was 134.5 ± 39.2 mg/dl, the mean
HDL was 41.1 ± 11.6 mg/dl, the mean total cholesterol was
227.4 ± 54.9 mg/dl, and the mean triglycerides were
210.3 ± 73.0 mg/dl. The mean creatinine clearance in whole
cohort was 99.9 ± 22.9 ml/min. HbA1c was done for all
patients to evaluate the diabetic control. In group I the
mean ± SD of HbA1c was 7.54 ± 0.75% and in group II, it
was 7.42 ± 0.96% and it was statistically non-signiﬁcant
between the two groups (p= 0.52). Contrast-induced
nephropathy post-PCI occurred in 12 (15%) patients. The
two groups were similar regarding all laboratory data, as well
as the incidence of post-PCI contrast-induced nephropathy
(p> 0.05 for all).
According to the previously mentioned deﬁnition, the inci-
dence of post-PCI contrast-induced nephropathy was not sig-
niﬁcantly different between the two study groups (p> 0.05).
Univariate regression analysis identiﬁed the following as
predictors of contrast-induced nephropathy: baseline blood
urea (p= 0.012), blood urea after 12 h (p= 0.030), and blood
urea after 72 h (p= 0.003).
Multivariable regression analysis did not identify any inde-
pendent predictor of contrast-induced nephropathy (p> 0.05
for all) (see Fig. 1 and Table 3).
ROC curve analysis showed that optimal cutoff value of
baseline serum creatinine that best predicts CIN was 1.2 mg/
dl. Serum creatinine level more than 1.2 mg/dl predicted CIN
with sensitivity 41.7%, speciﬁcity 89.7%, PPV41.7%, NVP
89.7%, and diagnostic accuracy 82.50%. The optimal cutoff
value of creatinine clearance that best predicts CIN was
104 ml/min. Creatinine clearance less than 104 ml/mine two study groups.
Group A N= 40 Group B N= 40 p Value
29(72.5%) 35(87.5%) 0.094
56.88 ± 9.99 55.85 ± 8.42 0.621
83.13 ± 11.63 88.63 ± 12.41 0.044*
23(57.5%) 26(65.0%) 0.491
20(50.0%) 21(52.5%) 0.823
19(47.5%) 18(45.0%) 0.823
8 ± 2.4 9 ± 4.1 0.19
24(60.0%) 25(62.5%) 0.818
16(40.0%) 15(37.5%)
238.25 ± 39.93 244.25 ± 33.50 0.469
tion, IHD= ischemic heart disease.
Table 2 Laboratory data of the whole cohort and the two study groups.
Whole cohort N= 80 Group A N= 40 Group B N= 40 p Value
Creatinine on admission (mg/dl) 1.1 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 0.431
Creatinine after 12 h (mg/dl) 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.2 0.836
Creatinine after 72 h (mg/dl) 1.2 ± 0.3 1.2 ± 0.2 1.2 ± 0.4 0.716
Urea on admission (mg/dl) 34.0 ± 9.9 34.7 ± 9.5 33.3 ± 10.4 0.117
Urea after 12 h (mg/dl) 35.0 ± 8.9 35.1 ± 7.2 35.0 ± 10.4 0.209
Urea after 72 h (mg/dl) 34.5 ± 9.7 34.5 ± 6.5 34.6 ± 12.2 0.275
SGOT (mg/dl) 29.8 ± 6.5 29.2 ± 6.1 29.8 ± 6.9 0.659
SGPT (mg/dl) 35.7 ± 9.7 36.2 ± 9.9 35.2 ± 9.6 0.648
LDL (mg/dl) 134.5 ± 39.2 131.5 ± 41.9 137.4 ± 36.5 0.508
HDL (mg/dl) 41.2 ± 11.6 40.0 ± 11.9 41.5 ± 11.3 0.723
TG (mg/dl) 210.3 ± 73.0 209.2 ± 56.3 211.5 ± 87.4 0.654
Total cholesterol (mg/dl) 227.4 ± 54.9 231.80 ± 53.0 223.1 ± 57.2 0.481
HbA1c 7.54 ± 0.75 7.42 ± 0.96 0.52
Baseline creatinine clearance (ml/min) 99.9 ± 22.9 95.8 ± 20.1 104.0 ± 24.9 0.166
Incidence of CIN 12(15%) 5(12.5%) 7(17.5%) 0.531
LDL= low density lipoproteins, HDL= high density lipoproteins, TG= triglycerides, CIN= contrast induced nephropathy,
SGOT= Serum glutamic oxaloacetic transaminase, SGPT= serum glutamic-pyruvic transaminase, HbA1c = glycated hemoglobin.
AUC= Area under the curve
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Figure 1 ROC curve analysis of optimal cutoff value of creatinine level and creatinine clearance on admission to predict contrast
induced nephropathy.
Table 3 Accuracy parameters (sensitivity, speciﬁcity, PPV, NPV and accuracy) for the optimal cutoff value of creatinine and
creatinine clearance on admission that best predicts CIN.
Sensitivity Speciﬁcity PPV NPV Accuracy
Creatinine on admission >1.2 mg/dl 41.7 89.7 41.7 89.7 82.50
Creatinine clearance <104 ml/min 50.0 77.9 28.6 89.8 73.8
CIN= contrast induced nephropathy, PPV = positive predictive value, NPV= negative predictive value.
332 H. Galal et al.predicted CIN with sensitivity 50%, speciﬁcity 77.9%, PPV
28.6%, NVP 89.8%, and diagnostic accuracy 73.8%.
ROC curve analysis showed that the optimal cutoff value of
serum urea on admission that best predicts CIN was 36 mg/dl.
Serum urea on admission more than 36 predicted CINwith sen-sitivity 58.3%, speciﬁcity 79.4%, PPV 33.3%, NVP 91.5%, and
diagnostic accuracy 76.3%, while optimal cutoff value of serum
urea after 12 h that best predicts CIN was 37 mg/dl. Serum urea
after 12 h more than 37 predicted CIN with sensitivity 66.7%,
speciﬁcity 72.0%, PPV 29.6%, NVP 92.5%, and diagnostic
AUC p
Urea on admission 0.705* 0.024
Figure 2 ROC curve analysis of optimal cutoff value of serum
urea on admission that best predicts contrast induced
nephropathy.
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72 h that best predicts CIN was 36 mg/dl. Serum urea after
72 h more than 36 predicted CIN with sensitivity 58.3%, spec-
iﬁcity 80.9%, PPV 35%, NVP 91.7%, and diagnostic accuracy
77.5% (see Figs. 2 and 3 and Table 4).
3. Discussion
CIN is the third leading cause of all cases of hospital-acquired
renal failure.12 Although11 its incidence is low in patients with
normal renal function, it can be much higher in those with
severe renal insufﬁciency at baseline. The traditional deﬁnition
of CIN has been an absolute rise of serum creatinine (Cr) of
P0.5 mg/dl, recent clinical trials have used a P25% increase
from baseline Cr.13 Patients undergoing percutaneous coro-
nary interventions (PCI) have a higher mortality rate if
nephropathy develops.14 The risk of dying is greatest in
patients who require dialytic support because of the nephrop-
athy. The best approach to prevent CIN is to identify at-risk
patients, provide adequate peri-procedural hydration, and
minimize the amount of contrast administered. Multiple pre-
ventive measures have been evaluated, with very few of them
being efﬁcient in reducing CIN rates.
The beneﬁcial effects of statins are not only related to lipid-
lowering even if this seems to be beneﬁcial in patients with ACS
but also to direct effects on endothelial function, oxidative
stress, inﬂammation, thrombosis as well as plaque stabiliza-
tion.15–18
In our study, the incidence of post-PCI contrast-induced
nephropathy was not signiﬁcantly different between high and
low doses atorvastatin (p> 0.05). Multivariable regressionTable 4 Accuracy parameters (sensitivity, speciﬁcity, PPV, NPV an
after 12 h and after 72 h to predict CIN.
Sensitivity Spe
Urea on admission >36 mg/dl 58.3 79.4
Urea after 12 h >37 mg/dl 66.7 72.0
Urea after 72 h >36 mg/dl 58.3 80.9
CIN= contrast induced nephropathy, PPV= positive predictive value,analysis did not identify any independent predictor of con-
trast-induced nephropathy (p> 0.05).
In agreement with our study, Jo et al.19 enrolled 247 consec-
utive patients with chronic renal insufﬁciency undergoing cor-
onary angiography. They were randomized to simvastatin
(n= 124; 160 mg total, 40 mg orally every 12 h starting the
evening before and ending the morning after the procedure)
or placebo (n= 123). They found that high-dose simvastatin
pretreatment for short-term did not prevent renal function
deterioration after administration of contrast medium in
patients with baseline renal insufﬁciency undergoing coronary
angiography. Similarly, in a prospective, single-center study by
Toso et al.20 304 patients with baseline estimated creatinine
clearance <60 ml/min were randomized to receive atorvastatin
80 mg/day or placebo for 48 h before and 48 h after contrast
medium administration. CIN occurred in 31 patients (10%),
16 (11%) in the placebo group and 15 (10%) in the atorva-
statin group (p= 0.86). In concordance with our results, they
concluded that short-term administration of high doses of
atorvastatin before and after contrast exposure, in addition
to standard intravenous hydration and oral N-acetylcysteine,
do not decrease CIN occurrence in patients with pre-existing
chronic kidney disease.
Bouzas-Mosqueret al.21 evaluated 589 consecutive patients
with acute myocardial infarction who underwent primary angi-
oplasty at their institution. The incidence of CIN in the group
on statins was 15.9%, as compared with 10.8% in the group
not taking statins (p= 0.2). Again, similar to our results, they
concluded there is no protective effect of statin therapy on
CIN development after primary angioplasty.
In contrast to our ﬁndings, Zhang et al.22 documented the
effectiveness of short-term high-dose statin pretreatment for
both decreasing the level of serum creatinine and reducing
the rate of CIN in patients undergoing diagnostic and inter-
ventional procedures requiring contrast media. The different
results can be explained by differences in sample size, and pop-
ulation characteristics: our study cohort were all diabetic
patients, had normal or mild baseline renal dysfunction, and
underwent early PCI for acute non-ST elevation acute coro-
nary syndrome.
Compared with our study, Xinwei et al.23 evaluated 228
patients with acute coronary syndrome undergoing PCI who
were randomly divided into simvastatin 20-mg group
(n= 115) and simvastatin 80-mg group (n= 113). It con-
cluded that pretreatment with simvastatin 80 mg before PCI
could further decrease the occurrence of CIN, compared with
simvastatin 20 mg (p< 0.001). This disagreement of results
might be explained in view of the smaller sample size of our
cohort, the fact that our patients were all diabetic, and the
enrollment of patients with mild renal impairment in our
cohort. Moreover, the study by Xinwei et al. employed simva-
statin as the study drug, versus atorvastatin in our study.d accuracy) for the optimal cutoff value of urea on admission,
ciﬁcity PPV NPV Accuracy
33.3 91.5 76.3
29.6 92.5 71.3
35.0 91.7 77.5
NPV= negative predictive value.
AUC p
Urea after 12 hours 0.697* 0.031
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Figure 3 ROC curve analysis of optimal cutoff value of serum urea after 12 h and after 72 h that best predicts contrast induced
nephropathy.
334 H. Galal et al.Zhao et al.24 investigated 279 consecutive patients who
underwent successful primary PCI for a ﬁrst AMI. 56 patients,
already receiving statin treatment before admission, had a
lower incidence of CIN, versus those who did not receive it
(7.1% and 20.6%, P< 0.01). In our study, the incidence of
CIN was (12.5% and 17.5%, respectively, p> 0.05). They
concluded that pre-treatment with statin could reduce CIN
after primary PCI in patients with AMI. The divergence of
results from our study might be explained by differences in
population characteristics, and also by the difference in sample
size. Moreover, the retrospective nature of the study by Zhao
et al. may need further conﬁrmation in prospective random-
ized trials. Yoshida et al.25 evaluated 431 consecutive patients
(367 men and 64 women) with renal insufﬁciency (undergoing
scheduled coronary angiography or PCI. They reported that
pravastatin treatment before contrast media exposure was an
important factor associated with the reduction in CIN after
coronary angiography or PCI in patients with cardiovascular
disease and renal insufﬁciency. The different ﬁndings com-
pared with our ﬁndings, can be explained in the light of the
population enrolled in that study (stable patients undergoing
elective procedures), and the different statin used (pravastatin).
Pappy et al.26 searched MEDLINE and EMBASE dat-
abases through December 2010 for articles evaluating the
effect of statins on the incidence of CIN in patients undergoing
coronary angiography. Odds ratios (OR) with 95% conﬁdence
intervals (CI) were calculated using random effects modeling.
Three randomized controlled trials involving 770 patients
(330 in the statin group and 340 in the control group) and 7
non-randomized studies involving 31,959 patients (11,936 sta-
tin-pretreated and 20,023 statin-naı¨ve) were included in the
pooled analysis. Based on the pooled estimate across the 3 ran-
domized controlled trials, statin therapy did not signiﬁcantly
reduce the incidence of CIN compared to control
(OR = 0.76, 95% CI: 0.41–1.41, p= 0.39). No signiﬁcant het-
erogeneity was found in the randomized studies (I2 = 0%,
p= 0.48). The pooled analysis of the non-randomized studies
showed a marginally signiﬁcant beneﬁt associated with statin
therapy (OR= 0.60, 95% CI: 0.36–1.00, p= 0.05). There
was signiﬁcant heterogeneity among the non-randomized stud-
ies (I2 = 88%, p< 0.00001). No solid conclusion could bedrawn from that pooled analysis on a beneﬁcial effect of statin
therapy on the incidence of CIN in patients undergoing PCI.
Khanal et al.27 studied 29,409 patients who had both base-
line pre-procedural and peak post-procedural serum creatinine
measured at the time of their PCI. When compared with
patients who did not receive pre-procedural statins, patients
on pre-procedural statins had a lower incidence of CIN (4.37
versus 5.93, P< 0.0001) and nephropathy requiring dialysis
(0.32 versus 0.49, P= 0.03). After adjustments for comorbid-
ities, pre-procedural statin was associated with a signiﬁcant
reduction of CIN (odds ration [OR] 0.87, 95% conﬁdence
interval [CI] 0.77–0.99, P= 0.03). The large sample size of
that study, the differences in baseline characteristics (as men-
tioned before), and the retrospective nature of their study,
might all underlie the different results. In the study by Patti
et al.28 statin-naive patients with acute coronary syndrome
undergoing PCI (n= 241) randomly received atorvastatin
(80 mg 12 h before intervention with another 40-mg pre-proce-
dural dose, n= 120) or placebo (n= 121). All patients had
long-term atorvastatin treatment thereafter (40 mg/day). Five
percent of patients in the atorvastatin arm developed CIN, ver-
sus 13.2% with placebo, p= 0.046). Comparative ﬁgures in
our study were 12.5% in the high-dose statin group, and
17.5% in the low-dose statin group, P> 0.05. They concluded
that short-term pretreatment with high-dose atorvastatin load
prevents CIN and shortens hospital stay in patients with acute
coronary syndrome undergoing PCI. However, the different
results could be explained by the fact that we enrolled diabetic
patients, some of whom had mild renal impairment at baseline.
Another crucial difference was the fact that the comparing
group in their study received placebo, whereas in our study
the comparing group received low-dose statin.
An updated meta-analysis was done by Xie et al. to inves-
tigate the effect of statins in preventing contrast-induced
nephropathy (CIN) and the results were conﬂicting. Systematic
database searches of MEDLINE (1950 to December 2013),
EMBASE (1966 to December 2013), and the Cochrane Central
Register of Controlled Trials (Issue 12, December 2013) were
performed. All randomized controlled trials assessing the efﬁ-
cacy of statins on CIN including 6323 patients were included.
They concluded that pretreatment with statins before angiog-
Impact of atorvastatin on CIN in diabetic patients 335raphy is effective in preventing CIN and may reduce the risk of
adverse clinical events. However, the optimal dose and dura-
tion for statin pretreatment are still unknown.29
4. Summary
In our study, we explored the effect of short term high dose
atorvastatin pretreatment to prevent CIN in diabetic patients
with normal or mild renal impairment presenting with non
ST elevation acute coronary syndrome who underwent early
PCI (within 48 h). The study included 80 consecutive diabetic
patients. All patients had type II diabetes and they were ran-
domly assigned to one of two groups, Group (A) [40 patients]
received 80 mg atorvastatin 12 h and 40 mg just before PCI.
Group (B) [40 patients] continued on 10 mg atorvastatin at
the same time points. The design was single-blinded random-
ized controlled trial. Investigators were aware of allocation
group, while patients were blinded. The method of randomiza-
tion was consecutive repetition, for example (patient 1 in
group A, 2 in group B, 3 in group A, etc). After statistical anal-
ysis there were 5 cases of CIN in group A (12.5%) versus 7 in
group B (17.5%), (p> 0.05). Multivariable regression analysis
did not identify any independent predictor of CIN (p> 0.05).
We concluded that there was no signiﬁcant difference between
high and low doses of atorvastatin in decreasing the incidence
of CIN in diabetic patients with normal or mild renal impair-
ment presenting with non ST acute coronary syndrome and
who underwent early PCI.5. Study limitations
1. Our ﬁndings are based on a single center study.
2. Sample size of the cohort is relatively small.
3. Our ﬁndings cannot be extrapolated to patients with more
severe impairment of renal function, since our cohort
included patients with normal or mildly impaired renal
function.
4. Our ﬁndings in patients with type 2 diabetes mellitus may
not be generalized to those with type 1 diabetes mellitus.
5. Mid-term and long-term follow-up is needed to explore the
remote clinical outcome.
6. Conclusion
 Our ﬁndings suggest that there is no signiﬁcant difference
between high-dose and low-dose atorvastatin to prevent
contrast induced nephropathy in diabetic patients present-
ing with non-ST acute coronary syndrome undergoing early
PCI, who have normal or mildly impaired renal function.
 The role of short-term high-dose statin use to prevent con-
trast induced nephropathy is still controversial.
7. Recommendations
 High dose statins are better than low dose statins in acute
coronary syndrome as recommended by the guidelines of
American College of Cardiology and European Society of
Cardiology. All preventive measures for CIN must be taken in diabetic
patients presenting with non ST elevation acute coronary
syndrome, because the incidence CIN in these patients is
not low.
 Large prospective multicenter randomized controlled trials
with adequate statistical power, examining the same proto-
col is needed before solid conclusions are drawn.
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